SWOG 9713:CISPLATIN & ETOPOSIDE & CONCURRENT RADIOTHERAPY FOR SMALL C

小细胞肺癌占所有肺癌诊断的25%。这些患者中有三分之一表现为有限期疾病，并被认为有可能通过目前的治疗治愈。 尽管同步放化疗可改善预后，但大多数患者仍会发生疾病进展。 指出了新的方法。 本研究将评估卡铂和紫杉醇作为巩固治疗SCLS的使用。 诱导方案与SWOG 8991相似。 巩固治疗将包括紫杉醇，剂量为200 mg/m2，持续3小时，然后是卡铂，AUC为6。 将使用顺铂和依托泊苷的双药诱导方案，而先前试验使用含长春新碱的方案。 放射治疗的总剂量将增加到6,100 cGy。 本研究将使用先前确立的SWOG有限疾病定义，包括恶性胸腔积液患者。

Small cell lung cancer accounts for 25% of all lung cancer diagnoses. One-third of those patients present with limited stage disease and are considered potentially curable with current therapy. Despite improved outcome with concurrent chemoradiotherapy, the majority of patients will develop progressive disease. Novel approaches are indicated. This study will evaluate the use of carboplatin and paclitaxel as consolidative therapy in the treatment of SCLS. The induction schema will be similar to that of SWOG 8991. Consolidation therapy will include Paclitaxel at a dose of 200 mg/m2 over three hours followed by carboplatin at an AUC of six. A two-drug induction regimen of cisplatin and etoposide will be utilized versus prior trials utilizing a vincristine-containing regimen. Radiotherapy will be increased to a total dose of 6,100 cGy. The study will utilize the previously established SWOG definition of limited disease which includes patients with malignant pleural effusions.